Evidence map›Paper›PMID 38483012›Full record

ReviewHistology and histopathology2024

The immune microenvironment of cancer of the uterine cervix.

Michail Mastrogeorgiou, Elena Chatzikalil, Stamatios Theocharis, Alexandra Papoudou-Bai, Michel Péoc'h, Mousa Mobarki, Georgia Karpathiou

Abstract readReview
PubMed Publisher
In one paragraph

Review in Histology and histopathology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 3 countries.

Michail MastrogeorgiouFirst Department of Pathology, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Elena ChatzikalilFirst Department of Pathology, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Stamatios TheocharisFirst Department of Pathology, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Alexandra Papoudou-BaiDepartment of Pathology, Faculty of Medicine, University of Ioannina, Ioannina, Greece.
Michel Péoc'hDepartment of Pathology, University Hospital of Saint-Etienne, Saint-Etienne, France.
Mousa MobarkiDepartment of Pathology, Faculty of Medicine, Jazan University, Jazan, Saudi Arabia.
Georgia KarpathiouDepartment of Pathology, University Hospital of Saint-Etienne, Saint-Etienne, France. georgia.karpathiou@chu-st-etienne.fr.
National and Kapodistrian University of Athens · GRCentre Hospitalier Universitaire de Saint-Étienne · FRJazan University · SAUniversity of Ioannina · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

While several treatment choices exist for cervical cancer, such as surgical therapy, chemotherapy, and radiotherapy, some patients will still show poor prognosis. HPV infection is a principal factor for cervical cancer development, from early inflammation to proliferation, angiogenesis, and neoplastic growth. While HPV T-cell responses exist, the tumor seems to evade the immune system upon its tolerance. The latter suggests the existence of a confluent tumor microenvironment responsible for the evasion tactics employed by the neoplasm. Therefore, novel biomarkers governing prognosis and treatment planning must be developed, with several studies tackling the significance of the tumor microenvironment in the genesis, development, proliferation, and overall response of cervical cancer during neoplastic processes. This review aims to analyze and contemplate the characteristics of the tumor microenvironment and its role in prognosis, progression, evasion, and invasion, including therapeutic outcome and overall survival.

Indexed as

Tumor MicroenvironmentUterine Cervical NeoplasmsFemaleHumansPapillomavirus InfectionsPrognosis

Identifiers

PMID38483012
OpenAlexW4394768263

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.